Anil Singhal

AbbVie Inc

关注

立即认领

关注

立即认领

基本信息

浏览量：64

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 58 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

Table S1 from First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

Ravi Vij,Rajneesh Nath,Daniel E.H. Afar,María-Victoria Mateos,Jesús G. Berdeja,Marc S. Raab,Andreas Guenther,Joaquín Martínez-López,Andrzej J. Jakubowiak,Xavier Leleu,Katja Weisel,Shekman Wong,Scott Gulbranson,James P. Sheridan,Anita Reddy,Bruno Paiva,Anil Singhal, Jesús F. San-Miguel,Philippe Moreau

openalex（2023）

引用0浏览0引用

Figure S1 from First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

openalex（2023）

引用0浏览0引用

Elotuzumab, Lenalidomide, and Dexamethasone in RRMM: Final Overall Survival Results from the Phase 3 Randomized ELOQUENT-2 Study

Meletios A. Dimopoulos,Sagar Lonial,Darrell White,Philippe Moreau,Katja Weisel,Jesus San-Miguel,Ofer Shpilberg,Sebastian Grosicki,Ivan Špička,Adam Walter-Croneck,Hila Magen,Maria-Victoria Mateos,Andrew Belch,Donna Reece,Meral Beksac,Andrew Spencer,Heather Oakervee,Robert Z. Orlowski,Masafumi Taniwaki,Christoph Röllig,Hermann Einsele,Morio Matsumoto,Ka Lung Wu,Kenneth C. Anderson,Ying-Ming Jou,Alex Ganetsky,Anil K. Singhal,Paul G. Richardson

Blood Cancer Journal（2020）

引用121浏览0WOSNATURE引用

121

Data from First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

Ravi Vij,Rajneesh Nath,Daniel E. H. Afar,Maria Victoria Mateos,Jesus G. Berdeja,Marc S. Raab,Andreas Guenther,Joaquin Martinez-Lopez,Andrzej J. Jakubowiak,Xavier Leleu,Katja Weisel,Shekman Wong,Scott Gulbranson,James P. Sheridan,Anita Reddy,Bruno Paiva,Anil Singhal,Jesus F. San-Miguel,Philippe Moreau

Clinical Cancer Research（2020）

引用23浏览0WOS引用

Elotuzumab Plus Lenalidomide/dexamethasone for Relapsed/refractory Multiple Myeloma: Final Overall Survival Results from the Phase 3 ELOQUENT-2 Trial

Meletios A. Dimopoulos,Katja Weisel,Sagar Lonial,Darrell White,Philippe Moreau,Maria-Victoria Mateos,Jesus San-Miguel,Kenneth C. Anderson,Ofer Shpilberg,Sebastian Grosicki,Ivan Spicka,Adam Walter-Croneck,Hila Magen,Andrew Belch,Donna Reece,Meral Beksac,Alex Ganetsky,Ying-Ming Jou,Mihaela Popa McKiver,Anil K. Singhal,Paul G. Richardson

Clinical Lymphoma Myeloma & Leukemia（2019）

引用8浏览0引用

Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (eld) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM)

Sagar Lonial,Meletios Dimopoulos,Katja Weisel,Darrell White,Philippe Moreau,Maria-Victoria Mateos,Jesus San Miguel,Kenneth Anderson,Ofer Shpilberg,Sebastian Grosicki,Ivan Spicka,Adam Walter-Croneck,Hila Magen,Andrew Belch,Donna Reece,Meral Beksac,Suresh Shelat,Oumar Sy,Anil Singhal,Paul Richardson

Journal of Clinical Oncology（2018）

引用9浏览0引用

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free …

Meletios A Dimopoulos,Sagar Lonial,Darrell White,Philippe Moreau,Antonio Palumbo,Jesus San‐Miguel,Ofer Shpilberg,Kenneth Anderson,Sebastian Grosicki,Ivan Spicka,Adam Walter‐Croneck,Hila Magen,Maria‐Victoria Mateos,Andrew Belch,Donna Reece,Meral Beksac,Eric Bleickardt,Valerie Poulart,Jennifer Sheng,Oumar Sy,Jessica Katz,Anil Singhal,Paul Richardson

British journal of haematologyno. 6 (2017): 896-905

引用125浏览0引用

125

Elotuzumab Plus Lenalidomide/dexamethasone for Relapsed or Refractory Multiple Myeloma: ELOQUENT‐2 Follow‐up and Post‐hoc Analyses on Progression‐free Survival and Tumour Growth

Meletios A. Dimopoulos,Sagar Lonial,Darrell White,Philippe Moreau,Antonio Palumbo,Jesus San-Miguel,Ofer Shpilberg,Kenneth Anderson,Sebastian Grosicki,Ivan Spicka,Adam Walter-Croneck,Hila Magen,Maria-Victoria Mateos,Andrew Belch,Donna Reece,Meral Beksac,Eric Bleickardt,Valerie Poulart,Jennifer Sheng,Oumar Sy,Jessica Katz,Anil Singhal,Paul Richardson

British Journal of Haematology（2017）

引用147浏览0WOS引用

147

Phase 3 ELOQUENT-2 Study: Extended Four Year Follow-Up (FU) of Elotuzumab Plus Lenalidomide/dexamethasone (eld) Vs Ld in Relapsed/refractory Multiple Myeloma (RRMM)

Sagar Lonial,Meletios A. Dimopoulos,Katja C. Weisel,Darrell White,Philippe Moreau,Maria-Victoria Mateos,Jesus San Miguel,Kenneth Carl Anderson,Ofer Shpilberg,Sebastian Grosicki,Ivan Spicka,Adam Walter-Croneck,Hila Magen,Andrew Belch,Donna Ellen Reece,Meral Beksac,Sabeen Mekan,Oumar Sy,Anil K. Singhal,Paul G. Richardson

Journal of Clinical Oncology（2017）

引用7浏览0引用

Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors

Elaine T. Lam,S. Gail Eckhardt,Wells Messersmith,Antonio Jimeno,Cindy L. O'Bryant,Ramesh K. Ramanathan,Glen J. Weiss,Manpreet Chadha,Abbie Oey, Han Ting Ding,Patricia A. Culp, Stephan F. Keller,Vivian Y. Zhao,L. Claire Tsao,Anil Singhal,Kyle D. Holen,Daniel Von Hoff

Molecular Cancer Therapeutics（2017）

引用18浏览0WOS引用

加载更多

作者统计

#Papers: 58

#Citation: 5664

H-Index: 26

G-Index: 54

Sociability: 6

Diversity: 2

Activity: 0

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn